|
|
New drug for schizophrenia.(Updates)(Invega (paliperidone) extended-release tablets; Janssen L.P.)(Brief article)
- Article from:
-
FDA Consumer
- Article date:
-
March 1, 2007
|
Copyright informationCOPYRIGHT 2007 U.S. Government Printing Office. This material is published under license from the publisher through the Gale Group, Farmington Hills, Michigan. All inquiries regarding rights should be directed to the Gale Group. (Hide copyright information)
|
Invega (paliperidone) extended-release tablets were approved in December 2006 to treat schizophrenia. Paliperidone is a new molecular entity, meaning that the medication contains an active substance that has never before been approved for marketing in any form in the United States. Paliperidone is the principal active metabolite of risperidone, a drug already marketed for treating schizophrenia.
Schizophrenia is a chronic, disabling mental disorder that affects more than 2 million Americans. Symptoms include hallucinations, delusions, disordered thinking, movement disorders, social withdrawal, and cognitive deficits, such as difficulty with perception, ...